Live Analyst Rating Changes 36215 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Kristen Kluska
CANT

Kristen Kluska

Cantor Fitzgerald
Wall Street Analyst
★★★☆☆
#1499
on 13Foresight · ranked by our own returns
42%
Success Rate
-3.5%
Average Return
32 of 77 calls profitable · +26.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 42% of Kristen Kluska's ratings turned a profit when each position was held for 1 year — averaging -3.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

125 Buy 21 Hold 0 Sell
Kristen's Stock Coverage 47 ratings · 2026-10-01
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
PTCT
PTC Therapeutics
 Sep 21, 2026 BUY Buy
+26.1% avg upside
29 analysts
$137.00
116.02% Upside
 -0.5% ·
MREO
Mereo Biopharma Group Plc
 Sep 17, 2026 BUY Strong Buy
+884.2% avg upside
11 analysts
$3.00
719.13% Upside
 +27.6% ·
ABEO
Abeona Therapeutics
 Sep 17, 2026 BUY Strong Buy
+230.0% avg upside
18 analysts
$30.00
483.03% Upside
 -6.1% ·
RARE
Ultragenyx Pharmaceutical
 Sep 17, 2026 BUY Strong Buy
+234.2% avg upside
36 analysts
$39.00
165.01% Upside
 +3.7% ·
SLDB
Solid Biosciences
 Sep 15, 2026 BUY Strong Buy
+132.1% avg upside
26 analysts
$26.00
276.28% Upside
 -12.9% ·
IRON
Disc Medicine
 Aug 31, 2026 BUY Strong Buy
+36.5% avg upside
21 analysts
$125.00
93.27% Upside
 -16.2% ·
CAPR
Capricor Therapeutics
 Aug 14, 2026 BUY Strong Buy
+199.7% avg upside
12 analysts
$28.00
215.75% Upside
 +25.7% ·
RNA
Atrium Therapeutics, Inc.
 Aug 13, 2026 BUY Strong Buy
+296.0% avg upside
5 analysts
$25.00
204.54% Upside
 -34.0% ·
MNPR
Monopar Therapeutics Inc
 Aug 12, 2026 HOLD Strong Buy
+33.9% avg upside
18 analysts
$119.00
52.06% Upside
 -30.4% ·
TSHA
Taysha Gene Therapies
 Aug 11, 2026 BUY Strong Buy
+191.4% avg upside
22 analysts
$19.00
295.85% Upside
 -26.3% ·
TSE:EPRX
Eupraxia Pharmaceuticals
 Aug 11, 2026 BUY Strong Buy
+74.9% avg upside
11 analysts
$26.97
131.92% Upside
 +21.0% ·
CDXS
Codexis
 Aug 11, 2026 BUY Strong Buy
+628.8% avg upside
13 analysts
$11.00
720.81% Upside
 -10.8% ·
RNAC
Cartesian Therapeutics
 Aug 06, 2026 BUY Strong Buy
+330.5% avg upside
19 analysts
$16.00
122.62% Upside
 -15.4% ·
CLDX
Celldex
 Aug 06, 2026 BUY Strong Buy
+31.9% avg upside
28 analysts
$61.00
89.86% Upside
 -22.0% ·
SRPT
Sarepta Therapeutics
 Aug 05, 2026 HOLD Buy
+233.0% avg upside
50 analysts
$21.00
19.38% Upside
 +17.2% ·
ZVRA
Zevra Therapeutics
 Aug 05, 2026 BUY Strong Buy
+105.2% avg upside
15 analysts
$25.00
134.21% Upside
 +4.2% ·
ADMA
ADMA Biologics
 Aug 05, 2026 HOLD Strong Buy
+9.4% avg upside
15 analysts
$12.00
19.96% Upside
 +8.7% ·
RIGL
Rigel
 Aug 04, 2026 HOLD Strong Buy
-43.6% avg upside
17 analysts
$43.00
10.62% Downside
 +24.5% ·
DBVT
DBV Technologies SA - American
 Jul 16, 2026 BUY Strong Buy
+108.7% avg upside
15 analysts
$48.00
327.80% Upside
 -21.7% ·
SUPN
Supernus Pharmaceuticals
 Jul 09, 2026 BUY Strong Buy
+29.7% avg upside
9 analysts
$67.00
57.97% Upside
 -8.5% ·
AQST
Aquestive Therapeutics
 Jun 25, 2026 BUY Strong Buy
+95.7% avg upside
10 analysts
$11.00
146.46% Upside
 +4.6% ·
SE:EGTX
Egetis Therapeutics AB
 Jun 25, 2026 BUY Strong Buy
+143.6% avg upside
1 analyst
$23.00
143.64% Upside
 +40.0% ·
QURE
uniQure
 Jun 17, 2026 BUY Strong Buy
+144.0% avg upside
30 analysts
 — -49.8% ·
LXEO
Lexeo Therapeutics, Inc.
 Mar 30, 2026 BUY Strong Buy
+465.5% avg upside
11 analysts
$19.00
468.78% Upside
 -37.2% ·
FULC
Fulcrum Therapeutics
 Mar 19, 2026 BUY Buy
+170.9% avg upside
14 analysts
$24.00
551.31% Upside
 -46.9% ·
SKYE
Skye Bioscience
 Mar 10, 2026 HOLD Strong Buy
+2860.4% avg upside
9 analysts
$16.00
899.98% Upside
 -73.9% ·
PHAT
Phathom Pharmaceuticals
 Jan 13, 2026 BUY Strong Buy
+243.7% avg upside
15 analysts
$29.00
303.33% Upside
 -53.3% ·
XFOR
X4 Pharmaceuticals
 Nov 21, 2025 BUY Strong Buy
+726.0% avg upside
16 analysts
$14.00
395.52% Upside
 -19.7% ·
HUMA
Humacyte
 Jul 01, 2024 BUY Strong Buy
+1197.3% avg upside
11 analysts
$7.00
1272.57% Upside
 -57.5% ·
IRD
Opus Genetics
 May 13, 2024 BUY Strong Buy
+144.5% avg upside
25 analysts
 — -42.9% ·
LCTX
Lineage Therap
 Feb 04, 2024 BUY Strong Buy
+488.5% avg upside
16 analysts
$6.00
553.20% Upside
 -36.5% ·
OTLK
Outlook Therapeutics
 Aug 30, 2023 HOLD Buy
+1534.3% avg upside
11 analysts
$20.00
3536.31% Upside
 +36.6% ·
DRTS
Alpha Tau
 Aug 28, 2023 BUY Strong Buy
-4.6% avg upside
5 analysts
$23.00
55.96% Upside
 -30.1% ·
ATNM
Actinium Pharmaceuticals
 Jun 28, 2023 BUY Strong Buy
+510.0% avg upside
11 analysts
$27.00
2310.63% Upside
 +0.5% ·
DMRA
Damora Therapeutics
 Jun 26, 2023 BUY Strong Buy
+43.4% avg upside
20 analysts
$17.00
16.76% Downside
 -80.6% ·
CMMB
Chemomab Therapeutics
 Jun 09, 2023 HOLD Strong Buy
+1956.3% avg upside
6 analysts
 — -41.7% ·
HEPA
Hepion Pharmaceuticals
 May 15, 2023 BUY Strong Buy
+43788.1% avg upside
9 analysts
$28.00
27899.94% Upside
 · ·
EVLO
Evelo Biosciences
 Mar 16, 2023 HOLD Buy
+44999900.0% avg upside
5 analysts
$20.00
19999899.97% Upside
 · ·
HTGMQ
HTG Molecular Diagnostics
 Mar 10, 2023 HOLD Strong Buy
+733333233.3% avg upside
6 analysts
 — · ·
HLSQ
Tessera Defense and Homeland Security
 Mar 10, 2023 HOLD Hold
+6137.5% avg upside
4 analysts
 — · ·
IBIO
Ibio
 Dec 21, 2022 HOLD Strong Buy
+407.5% avg upside
13 analysts
$10.00
769.49% Upside
 -84.8% ·
EOCN
Eocene
 Aug 04, 2022 HOLD Buy
+598.9% avg upside
13 analysts
$10.50
215.84% Upside
 · ·
ERNA
Eterna Therapeutics
 Dec 29, 2021 BUY Strong Buy
+2336.9% avg upside
4 analysts
$180.00
6085.65% Upside
 · ·
OCGN
Ocugen
 Sep 28, 2021 HOLD Strong Buy
+799.1% avg upside
17 analysts
$4.00
290.28% Upside
 -71.6% ·
MBIO
Mustang Bio
 May 12, 2021 BUY Strong Buy
+1357.9% avg upside
5 analysts
$10.00
2059.78% Upside
 · ·
SCPX
Scorpius Holdings
 Mar 02, 2021 BUY Strong Buy
+1831150.0% avg upside
11 analysts
$22.00
2199899.95% Upside
 · ·
EVGN
Evogene
 Nov 30, 2020 BUY Strong Buy
+2568.0% avg upside
6 analysts
$9.00
1955.67% Upside
 · ·
🔒 42 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Kristen Kluska — Frequently Asked Questions
How accurate are Kristen Kluska's stock ratings?
Based on the calls 13Foresight could measure, about 42% of Kristen's ratings were profitable over a one-year hold, with an average return of -3.5% per rating, or +26.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Kristen ranked on 13Foresight?
Kristen Kluska is currently ranked #1499 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kristen cover?
Kristen most recently has ratings on PTCT, MREO, ABEO, RARE, SLDB, IRON, CAPR, RNA, MNPR, TSHA, TSE:EPRX, CDXS and 35 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.